anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Monroes Sequence

Arc collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 33,236
Current window 19,831-19,860
Pages 1,108
Rows per page 30
Arc: Monroes Sequenceclear collectionreset all
18 30 60

Arc

19,831-19,860 of 33,236

filter-aware
20
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
21
The slide uses a three-column layout to explain the product, the strategy, and the clinical trial pipeline.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
22
The slide outlines a clinical trial structure with six cohorts testing different combinations of Dato-DXd, pembrolizumab, and platinum-based chemotherapy.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
23
Includes clinical trial abbreviations and definitions in the footer.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
24
The chart is a diverging stacked bar chart comparing two treatment arms. Yellow boxes highlight specific hematological toxicities.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
25
The slide uses a process flow diagram to map clinical trials to strategic goals.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
26
Includes spider plot (target lesion change over time) and waterfall plot (best percentage change).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
27
The slide uses a matrix-like layout to categorize clinical trials by disease stage and treatment line.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
28
The slide uses a matrix structure to segment the market by disease stage and molecular profile, overlaying clinical trial names (e.g., AEGEAN, FLAURA) as product markers.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
29
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
30
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
31
The slide uses a standard clinical trial flow diagram (process flow).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
32
Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
33
Clinical trial data presentation using Kaplan-Meier plots with associated risk tables and hazard ratios.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
34
The chart is a radial segment diagram showing patient population segments (HRD-negative, HRD-positive non-BRCAm, tBRCAm) and corresponding clinical trials.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
35
The slide outlines the clinical trial methodology, specifically the randomization and treatment arms for advanced endometrial cancer.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
36
The slide features headshots of the two presenters and a scientific illustration of the drug mechanism.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
37
The slide outlines a basket trial design for Enhertu across multiple solid tumor types.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
38
The table uses color-coded headers for different tumor types. The 'Best overall response' section is highlighted with a yellow border.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
39
The slide includes a summary table at the bottom showing Median Duration of Response (DoR) for the three patient cohorts.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
40
The chart is a classic waterfall plot used in oncology clinical trials to visualize tumor shrinkage.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
41
The chart uses a grouped bar structure to compare IHC 3+ and IHC 2+ prevalence ranges across 8 cancer types.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
42
Includes a headshot of the speaker and a medical illustration of blood cells/DNA.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
43
The slide illustrates the process of reweighting the ASCEND trial population to match the ALPINE trial population for a fair comparison.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
44
The slide uses a Kaplan-Meier curve for PFS and a forest plot for safety odds ratios.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
45
The slide is divided into two sections: Executive Leadership and Therapeutic Area Leadership.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
46
The slide uses a column-based layout to map specific drug brands and pipeline assets to five major oncology therapeutic areas.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
47
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
48
The slide uses a matrix-like structure to align patient segments (rows) with treatment stages (columns) and specific clinical trials (cells).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
49
The slide uses a matrix-like layout to map clinical trials (e.g., SERENA-4, CAPItello291) against disease stages and risk profiles.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit